Generic semaglutide race hinges on API supply as China leads: Goldman Sachs

The big unknown is whether CDMO capacity built for branded drugs gets diverted to generics, and whether SPPS can scale fast enough to meet a market Goldman models at ~99,000 kg of peptide API by 2030 ...
FiercePharma

Generics deal sounds alarm for foreign API makers

Foreign API makers unaccustomed to hosting FDA visitors may soon have to get their houses in order. A deal through which generics makers would pay $299 million in annual user fees to the FDA could ...
Asian News International

Generic semaglutide race hinges on API supply as china leads, global peptide demand to hit 99,000 kg by 2030: Goldman Sachs

New Delhi [India], June 7 (ANI): The speed of semaglutide genericisation and GLP-1 pricing after 2031/32 will likely depend less on demand and more on peptide API manufacturing capacity, Goldman Sachs ...
Business Wire

ChemWerth Appoints New General Sales Manager To Increase Its Generic API Footprint in India

WOODBRIDGE, Conn.--(BUSINESS WIRE)--ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its ...
India Infoline

Biocon considers selling its $1.5 billion generic API company

According to news report, Biocon is considering selling its generic active pharmaceutical ingredient (API) business, which is valued at approximately $1.5 billion, in order to lower its total debt.